Myomo (MYO) Small-Cap Growth Virtual Investor Conference summary

Market opportunity and medical need

• Upper limb paralysis affects over 3 million in the U.S., with 250,000 new chronic cases annually from stroke alone.

• Only 25,000–50,000 patients per year meet strict medical and insurance criteria for the device.

• Medicare coverage expansion now allows up to 500,000 patients in the prevalence pool to qualify.

• Two-thirds of strokes occur in those 65+, primarily covered by Medicare.

• Large unmet need for a portable, functional device for home and work use.

Reimbursement and regulatory milestones

• Medicare Part B now covers the device, doubling the addressable U.S. market.

• New CMS codes and published fees effective April 1, 2024, with $33,000–$65,000 per device.

• Medicare Advantage plans are now required to cover the device if medically necessary.

• International reimbursement progress, especially in Germany, with statutory insurers and social court support.

• Clinical research and patient registry data were key to securing expanded coverage.

Technology and intellectual property

• Device uses non-invasive EMG signals amplified up to 100,000x to restore motion.

• Originated from MIT and Harvard Medical School, with patents valid through 2039 in key markets.

• Custom-fabricated, 3D-printed devices tailored to each patient.